Onconetix, Inc.
ONCONASDAQHealthcareBiotechnology
Latest quote
$0.6492
−$0.0165 · -2.47%
ONCO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
49
Fair Value
Momentum
17
Strong Down
Sentiment
56
Mixed
Risk resilience
16
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOnconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- David Allan White
- Listed since
- Feb 18, 2022
- Employees
- 2
Market position
- Volume
- 225.62K
- 0.28× average
- Average volume
- 813.64K
- Average daily volume
- Market cap
- 2.33M USD
- Beta
- 2.69
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 250.82M USD
- P/E (TTM)
- -0.07×
- P/B (TTM)
- 0.11×
- P/S (TTM)
- 3.61×
- EV / EBITDA
- -18.91×
- Earnings yield
- -5.48%
- Free cash flow yield
- -3.78%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 80.40%
- Operating margin
- -1265.55%
- Net margin
- -1578.79%
- Return on equity
- -89.01%
- Return on assets
- -56.29%
- Return on invested capital
- -40.12%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 0.66×
ONCO news
ONCO peers
Continue in GoAI
Research ONCOresearch.disclaimer